Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 461 of 6351
-
New weekly shot aims to melt weight and soothe aching knees
Symptom relief Recruiting nowThe purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee osteoarthritis. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
New hope for tough lymphomas: experimental drug MDX2003 enters human testing
Disease control Recruiting nowThis study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma
Phase 1/2 • Sponsor: ModeX Therapeutics, An OPKO Health Company • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Blood test could personalize melanoma treatment, study hopes
Disease control Recruiting nowThe purpose of this study is to investigate the use of ctDNA measurements to guide first-lien therapy choice for patients with advanced or metastatic melanoma. Primary endpoints include progression-free survival. Secondary study endpoints include objective response rate and incid…
Phase 2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New hope for leukemia patients: drug cocktail shows promise
Disease control By invitation onlyThis phase II trial is to answer the question of "can adding the study drug, asciminib to usual treatment improve how chemotherapy works against Ph+ Acute Lymphoblastic Leukemia (ALL) and is this approach better than the usual approach for Ph+ALL?"
Phase 2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New study tests High-Tech glucose tracking to stop diabetes before it starts
Prevention Recruiting nowPrediabetes affects over one-third of adults in the United States, placing them at a higher risk for developing type 2 diabetes and heart disease, which can lead to serious health complications and increased medical costs. Although a program called the Diabetes Prevention Program…
Sponsor: State University of New York at Buffalo • Aim: Prevention
Last updated Jun 27, 2026 12:23 UTC
-
MRNA therapy offers hope for rare hormone disorder
Disease control Recruiting nowXH-02 is an mRNA nucleic acid drug that expresses PTH in the body following intravenous or subcutaneous injection, providing PTH replacement therapy for patients with hypoparathyroidism. Previous clinical studies have demonstrated the safety of subcutaneously administered XH-02 i…
Phase 2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could a gentle pill stop blood cancer before it starts?
Disease control Not yet recruitingClonal hematopoiesis (CH) is characterized by the overproduction of blood cells derived from a single hematopoietic stem and progenitor cell (HSPC) harboring certain somatic mutations. It is linked to serious outcomes, including cardiovascular disease, myeloid neoplasm (MN), and …
Phase 2 • Sponsor: Clinical Hub for Interventional Research (CHOIR) • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Could a smartphone app help treat a serious eating disorder?
Symptom relief Recruiting nowAvoidant/restrictive food intake disorder (ARFID) is a serious and impairing eating disorder - occurring in up to 4% of adults - for which most individuals do not have access to treatment. The proposed study aims to develop and test a mobile app to scale delivery of cognitive-beh…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Could a common diabetes pill protect the brain after a stroke?
Disease control Not yet recruitingBackground: Reperfusion therapies, including intravenous rt-PA and mechanical thrombectomy, significantly improve outcomes in acute ischemic stroke. However, these interventions also increase the risk of hemorrhagic transformation and malignant edema. Preclinical studies have de…
Phase 4 • Sponsor: Taichung Veterans General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug cocktail aims to tame a common blood cancer
Disease control Recruiting nowThe purpose of this prospective, multicenter, Phase 2 study is to evaluate the efficacy and safety of Mosunetuzumab in combination with the EZH2 inhibitor Zeprumetostat (SHR2554) in patients with follicular lymphoma (FL). The study plans to enroll approximately 80 patients, who w…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Could adding folic acid to salt prevent birth defects in zambia?
Prevention Recruiting nowQuestion: How effective is fortified iodized salt with folic acid (FISFA) in increasing serum and red blood cell folate in non-lactating, non-pregnant women of reproductive age in the country of Zambia who do not have active food fortification with a folic acid program? Particip…
Sponsor: University of Alabama at Birmingham • Aim: Prevention
Last updated Jul 01, 2026 00:00 UTC
-
Can vibration or gravity training help children with muscular dystrophy stand stronger?
Disease control Completedthis study aimed to mention Does whole-body vibration training or gravity-force stimulation produce greater improvements in postural stability among children with Duchenne Muscular Dystrophy?
Sponsor: Cairo University • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New immunotherapy cocktail takes on tough liver tumors
Disease control Recruiting nowRBS2418 is a targeted immune modulator that inhibits ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor immunity by preserving endogenous 2'-3' cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis, thereby ac…
Phase 2 • Sponsor: Riboscience, LLC. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Robot surgery may cut complication rates in penile cancer treatment
Disease control Recruiting nowOpen inguinal lymphadenectomy (O-ILAD) is the current standard of care for invasive staging and simultaneously the curative approach for patients with PeCa and elevated risk for or clinically detectable lymphatic disease in the groin. The high rate of complications of this surgic…
Sponsor: University Hospital Tuebingen • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug duo offers hope for advanced penile cancer patients
Disease control Recruiting nowThis phase II clinical study aims to evaluate the efficacy and safety of QL1706 in combination with lenvatinib in patients with previously treated advanced or metastatic penile squamous cell carcinoma. The primary objective of the study is to determine the median progression-fre…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Promising combo may keep rare melanoma at bay
Disease control Recruiting nowMelanoma has emerged as the fastest-growing malignancy in recent years, with incidence and mortality rates among both men and women in East Asian countries exceeding the Asian average. China ranks fifth among East Asian nations in melanoma incidence. Currently, immune checkpoint …
Phase 2 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Engineered immune cells take on tough autoimmune diseases
Disease control Recruiting nowThis study is a Phase 1/2, open-label clinical trial to test an experimental treatment called QEL-005 in adults with two autoimmune conditions: diffuse cutaneous systemic sclerosis (dcSSc) and difficult-to-treat rheumatoid arthritis (D2TRA). The main goals are to find out whether…
Phase 1/2 • Sponsor: Quell Therapeutics Limited • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New radiation therapy targets tough lung cancer tumors
Disease control Not yet recruitingNon-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide and accounts for approximately 80% of all lung cancer cases. Despite advances in chemotherapy, radiotherapy, and immunotherapy, the prognosis of patients with advanced-stage metastatic N…
Phase 2 • Sponsor: Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug SHR-A1811 tested in 1,000 lung cancer patients in Real-World setting
Disease control Not yet recruitingSHR-A1811 is an approved therapy for non-small cell lung cancer (NSCLC) in China. Despite the clinical trial evidence, there is no real-world data of SHR-A1811 used in Chinese lung cancer patients with HER2 alteration. This real world, prospective study will assess the effective…
Sponsor: Nanjing Tianyinshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Hope for Huntington's: new pill aims to tame harmful proteins
Disease control By invitation onlyThe goal of this clinical trial is to test if the drug SKY-0515, an oral medication, can lower harmful proteins linked to Huntington's Disease (HD) and improve the symptoms of participants with HD. This study includes men and women aged 25 and older who have HD confirmed by genet…
Phase 2/3 • Sponsor: Skyhawk Therapeutics, Inc. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC